Alzheimer’s Disease 1 in 9 people in the US aged 65 and older

Slides:



Advertisements
Similar presentations
Alzheimer’s Disease Edwin Onattu P. 3.
Advertisements

Etiopathogenesis of Alzheimer's disease
Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.
Alzheimer disease Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated April 2015.
Genetic Screening for Alzheimer’s Disease Thorstensen: Genetic Screening for Alzheimer's Disease 1.
ALZHEIMER'S DISEASE (AD)
Question: What do we know about the elusive nature of the pathogenesis of Alzheimer's disease? How can personalized medicine, or the application of genomics.
OXIDATIVE STRESS. INDUCTION OF OXIDATIVE STRESS Glutathione conjugation MalnutritionMutation Phagocytic activation Tissue damageSmoking.
CSF tau Is it an informative biomarker of AD pathology Chris Clark Alzheimer’s Disease Center University of Pennsylvania.
The Role of Beta Amyloid proteins in Alzheimer’s Disease What is A.D.?
Amyloid beta protein may initiate a cascade leading to AD pathology.
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Alzheimer’s Disease: Genetics, Pathogenesis, Models, and Experimental Therapeutics.
Aging, Memory and Alzheimer’s Disease Kinga Szigeti, MD, PhD.
The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. Susan A. Farr, et al.
ALZHEIMER’S DISEASE BY OLUFOLAKUNMI KEHINDE PRE-MD 1.
Progress Report on Alzheimer’s Disease Taking the Next Steps NIA NIH.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
Disorders with Complex Genetics. Signs & Symptoms: Memory loss for recent events Progresses into dementia  almost total memory loss Inability to converse,
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Alzheimer’s Disease By: Chelcy Branon. Facts  In 2006, there were 26.6 million sufferers worldwide  Costs 100 billion dollars per year.
Molecular mechanism for Alzheimer’s disease : searching for the possible therapeutic targets Sungkwon Chung Dept. of Physiology Sungkyunkwan Univ. School.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
Follow Up Questions Diabetes is caused by an increase in blood glucose. People with diabetes II also have a very high risk for developing Alzheimer’s disease.
Molecular Biology and Genetics of Amyotrophic Lateral Sclerosis Michael Sidel February 13, 2008.
Alzheimer’s Disease Gavin Mast, Musa Abdus-Samad, Arash Rezaeian, Sarah Rocha PHM142 Fall 2015 Instructor: Dr. Jeffrey Henderson.
Mason A. Israel et. al. Nature 2012
Epidemiology of Alzheimer’s Disease
Under the supervision of miklós jászberényi
Alzheimer disease Developed by Dr. June Carroll, Ms. Shawna Morrison and Dr. Judith Allanson Last updated Dec 2014.
Nitrones as potential therapeutic agents against Alzheimer’s Disease Dra. Alicia Merlino, Computational Chemistry Lab, Facultad de Ciencias, Universidad.
Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Genetic aspects of Alzheimer disease Karolina Pesz, Błażej Misiak, Maria M. Sasiadek Department of Genetics Wroclaw Medical University, Poland.
HOW CAN NEUROIMAGING HELP UNDERSTAND, DIAGNOSE, AND DEVELOP TREATMENTS FOR ALZHEIMER'S DISEASE? Part B – AD and brain systems NUCLEAR MEDICINE GRAND ROUNDS.
Alzheimer’s Disease (AD)
Alzheimer’s Disease and Cholesterol
The cholesterol-ceramide connection as a possible link between
Syed H. Omar, Christopher J. Scott, Adam S. Hamlin, Hassan K. Obied 
Title: Alzheimer’s disease and the social
Alzheimer’s Disease Putting the pieces together
Dementia Research and Enterprise at Liverpool John Moores University
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Alzheimer’s Disease CNS Block.
Research Proposal By Thomas Raymond
Seizures in Alzheimer’s disease
Creutzfeldt-Jakob Disease
Statin Selection Aimed to Reduce New-Onset DM Risk:
Frontotemporal Dementia
Q: How can we prevent or treat Alzheimer’s Disease?
Progress Report on Alzheimer’s Disease
Cerebral Palsy (CP) Disorder of movement, muscle tone or posture that is caused by an insult to the immature, developing brain, most often before birth.
Immunotherapeutic Approaches for Alzheimer’s Disease
Disorders with Complex Genetics
Nat. Rev. Neurol. doi: /nrneurol
Acetylation Unleashes Protein Demons of Dementia
Probing the Biology of Alzheimer's Disease in Mice
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
The Role of Apolipoprotein E in Alzheimer's Disease
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups.
Figure 2 Comparison between noncarriers (−) and carriers (+) of the minor allele of rs (CYP2C19)‏ Comparison between noncarriers (−) and carriers.
Scott A. Small, Karen Duff  Neuron 
Tau Phosphorylation, Tangles, and Neurodegeneration
Mechanisms Underlying Inflammation in Neurodegeneration
New Frontiers in Alzheimer's Disease Genetics
Fyn-Tau-Amyloid: A Toxic Triad
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
2018 Alzheimer's disease facts and figures
in Younger and Older African Americans and Whites
Presentation transcript:

Alzheimer’s Disease 1 in 9 people in the US aged 65 and older 1 in 3 people aged 85 and older 2/3 are women Annual cost of more than 200 billion dollars By 2050 estimated to cost 1.2 trillion dollars annual Currently the 6th leading cause of death in the US. Familial (genetic) Alzheimer's disease (FAD) only accounts for ~15% of cases. The remaining are sporadic. APP and PSEN1/2 primary mutations for early onset AD (EAOD) APOe4 high risk for sporadic AD (>20x increase risk) (LOAD) Amyloid peptide thought to be the primary causative species Many types of amyloid peptide Many downstream effects such as Tau phosphorylation

Disease

? APP enhanced processing PSEN1/2 enhanced processing APOE cholesterol?!! Hypoxia ROS TAUphos

At mile high there is 17% less available oxygen than at sea level Percent increase in Alzheimer’s 2000-2010 (65+) and U.S. topographic map with values in feet above sea level (USGS). At mile high there is 17% less available oxygen than at sea level Hebert, L. E., P. A. Scherr, et al. (2004). "State-specific projections through 2025 of Alzheimer disease prevalence." Neurology 62(9): 1645.

Team Workshop 1: Find and write down the sequence of amyloid beta 1-42 (Ab42) and amyloid beta 1-40 (Ab40). Now use PASTA to predict the aggregation free energy of both peptides. Where in the sequence would you target a drug to inhibit aggregation?

Lovastatin Team Workshop 2: The use of statins has been accredited for the overall decrease in blood cholesterol and decreased cardiovascular diseases. Use the Cochrane library to determine if there is evidence linking statins to AD

Team Workshop 3: Use STRING to discover Tau interacting proteins that may play a role in Apoptosis of neurons and propose a mechanism for how Tau hyperphosporylation triggers apoptosis.

Nocodzol, taxol stabilizez microtubuels, image is structure of taxol Team Workshop 4: Determine the mechanism of nocodazole and compare this to hyperphosphorylation of Tau. Design an experiment to distinguish microtubule disassembly toxicity from Tau-NFT toxicity?

Remember Before 12 PM of the next class day: go to b.socrative.com/student/login and complete the quiz